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G protein-coupled receptors, or GPCRs, are a large superfamily of proteins found on the plasma membrane of cells.
They are involved in most physiological and pathophysiological functions and constitute the target of the majority
of marketed drugs. Although these receptors have been historically elusive to attempts of structural determination,
GPCR crystallography is now in full blossom, opening the way to structure-based drug discovery and enabling
homology modeling. This thematic issue of the journal In Silico Pharmacology, which illustrates how the expanding
body of structural knowledge is fostering complex computational analyses of the structure-function relationships of
the receptors and their interactions with their ligands, stems from the 31st Camerino-Cyprus-Noordwijkerhout
Symposium held in Italy, in May 2013, at the University of Camerino. Specifically, it originates from a session of the
symposium entitled “Structure-Based Discovery of Ligands of G Protein-Coupled Receptors: Finally a Reality”, and
features a mix of research articles and reviews on the application of computational modeling to the analysis of the
structure of GPCRs and the interactions of the receptors with their ligands.
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Molecular docking; Graph theoryG protein-coupled receptors, or GPCRs, are a large su-
perfamily of proteins found on the plasma membrane of
cells, i.e. the membrane that provides the border be-
tween the interior of a cell and the extracellular milieu
(Pierce et al. 2002). They are the object of the research
of the 2012 winners of the Nobel Prize in Chemistry
Robert Lefkowitz and Brian Kobilka, who, with their
seminal studies, gave a remarkable contribution to the
advancement of the body of knowledge surrounding
these receptor proteins.
Being located on the plasma membrane, GPCRs are
essential components of the mechanism that allows cells
to receive signals from their environment and react to
them and are involved in most physiological and patho-
physiological functions. Hence, they constitute the target
of the majority of the targeted drugs. The biological re-
sponse consequent the interaction of GPCRs with natural
ligands or drugs arises from the simultaneous modulationCorrespondence: costanzi@american.edu
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in any medium, provided the original work is pof a variety of signaling pathways. Some of these pathways
are mediated by the coupling of the receptors with in-
tracellular heterotrimeric guanine nucleotide binding pro-
teins known as G proteins, hence the name of GPCRs.
Moreover, studies pioneered by Robert Lefkowitz demon-
strated that alternative GPCR signaling pathways are me-
diated by the activation of proteins known as arrestins
(Pierce et al. 2002; Wisler et al. 2007; Kahsai et al. 2011;
Lefkowitz & Shenoy 2005; Martin et al. 2004; Reiter et al.
2012; Rajagopal et al. 2011; Drake et al. 2008; Lefkowitz
2013; Kobilka 2013).
Historically elusive to attempts of structural determi-
nation, GPCRs conceded for the first time to the efforts
of crystallographers in the year 2000, when Palczewski
and coworkers solved for the first time the three-dimen-
tional structure of rhodopsin (Palczewski et al. 2000).
Rhodopsin is a peculiar GPCR that, unlike most mem-
bers of the superfamily, is not activated by diffusible
ligands. Conversely, it is a photoreceptor naturally ac-
tivated by light, which triggers the isomerization of a
covalently bound inverse agonist, i.e. a molecule thatpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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i.e. a molecule that activates the receptor (Costanzi et al.
2009). Rhodopsin remained the only GPCR with ex-
perimentally elucidated structures until 2007, when the
first structures of the β2 adrenergic receptor were solved
(Cherezov et al. 2007; Rasmussen et al. 2007; Rosenbaum
et al. 2007). Thanks to the introduction of a number of ex-
pedients, which include the use of antibodies, fusion pro-
teins, stabilizing mutations and stabilizing ligands, GPCR
crystallography is now in full blossom (Stevens et al. 2013;
Katritch et al. 2013; Venkatakrishnan et al. 2013; Tate &
Schertler 2009; Kruse et al. 2013; Steyaert & Kobilka
2011). At the time of this writing, over 80 structures for
over 20 distinct receptors have been solved.
The GPCR structures that are now available are paving
the way for structure-based drug discovery, i.e. the ra-
tional identification of novel active molecules based on
computer-aided analyses of their interactions with their
target receptor (Mason et al. 2012; Congreve et al. 2011;
Congreve & Marshall 2009; Jacobson & Costanzi 2012;
Lane et al. 2013). Moreover, the GPCRs for which crystal
structures have been solved provide templates for the
construction of models for the remaining members of
the superfamily through a technique know as homology
modeling and based on the observation that the struc-
tures of evolutionarily related proteins, such as GPCRs
are, are closely related to each other (Costanzi & Wang
2014; Costanzi 2013; Costanzi 2010; Costanzi 2008).
This thematic issue of the journal In Silico Pharma-
cology, which illustrates how the expanding body of
structural knowledge is fostering complex computational
analyses of the structure-function relationships of the re-
ceptors and their interactions with their ligands, stems
from the 31st Camerino-Cyprus-Noordwijkerhout Sym-
posium held in Italy, in May 2013, at the University of
Camerino. Specifically, it originates from a session
of the symposium entitled “Structure-Based Discovery
of Ligands of G Protein-Coupled Receptors: Finally a Rea-
lity”. The issue is opened by an article from Giannella and
Angeli, who provide an insightful overview of the evolu-
tion of the field of GPCR studies observed from a very
special vantage point: the international symposia that are
regularly held in Camerino since the late 1970s (Giannella
& Angeli 2013). The opening piece is followed by three ar-
ticles that discuss the implications of the recent advance-
ments in GPCR crystallography for computer-aided ligand
discovery: a commentary from Jacobson that illustrates
the impact of the solution of GPCR structures on me-
dicinal chemistry efforts for the identification and the
development of modulators of pharmaceutically rele-
vant receptors (Jacobson 2013); an article from Mason,
Marshall and coworkers that demonstrates how the ra-
tional computer-assisted design of GPCR ligands is finally
enabled by the availability of GPCR structures as well asthe development of techniques that account for the in-
teraction of small molecules with the networks of water
molecules and lipophilic hotspots that characterize their
target receptors (Mason et al. 2013); an article from Dal
Ben, Volpini and coworkers that illustrates how molecular
docking targeting GPCR homology models derived from
the crystal structures of closely receptors can be applied
to the rationalization of structure-activity relationships,
thus setting the stage for drug design (Dal Ben et al.
2013). The special issue is closed by two articles that de-
scribe computational analyses enabled by the availability
of GPCR structures. The first one is an article from Floris,
Moro and coworkers, which describes the development of
a tool that, given a ligand of interest, facilitates the selec-
tion of the most suitable crystal structure for the study of
the interactions of the crystallized receptor with that
ligand or for the construction of a homology model of dif-
ferent receptor and the study of its interactions with that
ligand (Floris et al. 2013). The authors implemented the
tool in “Adenosiland”, a web-based platform dedicated to
GPCRs activated by the nucleoside adenosine. The second
one is an article from Sheftel, Costanzi and coworkers,
which describes how the structure of GPCRs can be ana-
lyzed through graph theory techniques to highlight their
structural features (Sheftel et al. 2013).
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